ReviewESMO open2022
How to read a next-generation sequencing report-what oncologists need to know.
Review in ESMO open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Reporting of somatic variants in clinical cancer care: recommendations of the Swiss Society of Molecular Pathology.Virchows Archiv : an international journal of pathology · 2024Guideline
- From free text to structured genomics: future-proofing cancer registries for precision oncology.ESMO real world data and digital oncology · 2026Review
- Making sense of commercial genomic reports in oncology: a structured approach from clinical practice.Frontiers in oncology · 2026Article
- Article
- How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know.Journal of clinical medicine · 2025Review
- Validation and clinical evaluation of a comprehensive circulating tumor DNA assay for genomic profiling in solid tumors.BMC cancer · 2025Article
- Clinical application of CNV-seq for diagnosing abnormal brain development in children.Scientific reports · 2025Article
- Personalizing cancer therapy: the role of pharmacogenetics in overcoming drug resistance and toxicity.Molecular biology reports · 2025Review
- Development and challenges in the treatment of advanced gallbladder cancer (Review).Oncology letters · 2025Review
- Novel Approach to Proficiency Testing Reveals Significant Variations in Biomarker Practice Leading to Critical Differences in Lung Cancer Management.JTO clinical and research reports · 2025Article
- Laboratory validation of targeted next-generation sequencing assay for pathogen detection in lower respiratory infection.Microbiology spectrum · 2025Article
- Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use.International journal of molecular sciences · 2025Article
- Molecular testing and targeting for solid tumors with CNS metastases.Journal of neuro-oncology · 2025Review
- Oncogenic gene fusions in cancer: from biology to therapy.Signal transduction and targeted therapy · 2025Review
- Emerging molecular testing paradigms in non-small cell lung cancer management-current perspectives and recommendations.The oncologist · 2025Review
- The Impact and Performance of the Molecular Tumor Board: Three-Year Activity in Precision Medicine for Treatment of Patients with Cancer from the Marche Region, in Italy.Oncology and therapy · 2025Article
- Precision Oncology in Clinical Practice: Two Years of Comprehensive Genomic Profiling in Croatia.Journal of personalized medicine · 2025Article
- Examining the Formalin Fixation Method for Maintaining High RNA Quality in Surgical Lung Specimens.Thoracic cancer · 2025Article
- Molecular methods in cancer diagnostics: a short review.Annals of medicine · 2024Review
- Comparative Analysis of Generative Pre-Trained Transformer Models in Oncogene-Driven Non-Small Cell Lung Cancer: Introducing the Generative Artificial Intelligence Performance Score.JCO clinical cancer informatics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Next-generation sequencing (NGS) of tumor cell-derived DNA/RNA to screen for targetable genomic alterations is now widely available and has become part of routine practice in oncology. NGS testing strategies depend on cancer type, disease stage and the impact of results on treatment selection. The European Society for Medical Oncology (ESMO) has recently published recommendations for the use of NGS in patients with advanced cancer. We complement the ESMO recommendations with a practical review of how oncologists should read and interpret NGS reports. A concise and straightforward NGS report contains details of the tumor sample, the technology used and highlights not only the most important and potentially actionable results, but also other pathogenic alterations detected. Variants of unknown significance should also be listed. Interpretation of NGS reports should be a joint effort between molecular pathologists, tumor biologists and clinicians. Rather than relying and acting on the information provided by the NGS report, oncologists need to obtain a basic level of understanding to read and interpret NGS results. Comprehensive annotated databases are available for clinicians to review the information detailed in the NGS report. Molecular tumor boards do not only stimulate debate and exchange, but may also help to interpret challenging reports and to ensure continuing medical education.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.